19 May 2016 - Health Canada has approved the biologic treatment Entyvio (vedolizumab) to treat adults with moderate to severely active Crohn’s disease, the most common form of inflammatory bowel diseasei, offering an important new option for patients who don’t respond to or have failed on other treatments.

Entyvio was first approved by Health Canada last year for the treatment of ulcerative colitis, the second most common form of inflammatory bowel disease. Entyvio is the first and only gut-selective biologic therapy with no known systemic immunosuppressive effects and approved for use in adult CD patients who have had an inadequate response, loss of response or were intolerant to immunomodulators or a tumor necrosis factor-alpha antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

For more details, go to: http://www.takedacanada.com/media/news-releases/2016/entyvio-cd/